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(P = 0.013). Baseline performance in early PD discriminates 
fallers over 54 months, thereby identifying those at risk of 
falls. Clinical profiles for established and emergent fallers 
are to some extent distinct. These results reiterate the need 
for timely interventions to improve postural control and gait.
Keywords Parkinson’s disease · Falls · Prognosis · 
Characteristics
Introduction
Falls aetiology in people with Parkinson’s disease (PD) is 
complex and multidimensional. Falls are associated with pri-
mary features (age, disease severity, gait and balance deficit, 
cognitive impairment), and secondary features that occur in 
response to falling (anxiety, reduced self-efficacy, weakness 
and loss of mobility) [1]. To date, the strongest predictor of 
a future fall is a prior fall [2], and clinical fall assessment is 
typically triggered when falls are established and not prior 
to their occurrence. Although pragmatic, this approach is 
limited and important to recognise because effective falls 
management becomes more challenging when secondary 
features are established. Ideally, management of falls risk 
should begin early and aim to prevent or at least delay the 
onset of falls. The early natural history of falls and emerging 
risk factors is, however, poorly understood.
Responding to these concerns we reported on risk factors 
for falls in a cohort of falls-naïve, newly diagnosed people 
with PD [3]. We assessed falls over 36 months from diag-
nosis using monthly falls diaries alongside a comprehen-
sive battery of motor, cognitive and clinical measures. Slow 
gait speed, decreased stance time and Hoehn and Yahr III 
emerged as significant baseline predictors with 92% sensi-
tivity and 62% specificity. Risk of falling was almost eight 
Abstract The natural history of falls in early Parkinson’s 
disease (PD) is poorly understood despite the profound 
effect of falls on outcome. The primary aim of this study 
was to describe the natural history of falls, and characterise 
fallers over 54 months in 99 newly diagnosed people with 
PD. Seventy-nine (79.7%) participants fell over 54 months 
and 20 (20.3%) remained falls-naïve. Twenty six (26.2%) 
reported retrospective falls at baseline. Gait outcomes, dis-
ease severity and self-efficacy significantly discriminated 
across groups. Subjective cognitive complaints emerged as 
the only significant cognitive predictor. Without exception, 
outcomes were better for non-fallers compared with fallers 
at any time point. Between group differences for 54 month 
fallers and non-fallers were influenced by the inclusion of 
retrospective fallers and showed a broader range of discri-
minant characteristics, notably stance time variability and 
balance self-efficacy. Single fallers (n = 7) were significantly 
younger than recurrent fallers (n = 58) by almost 15 years 
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times higher for people presenting with these characteristics. 
Cognition did not feature as a risk factor despite recent evi-
dence supporting a clear role in falls prediction [4–6] and in 
promoting effective falls intervention programmes [7] pos-
sibly because the level of cognitive impairment did not reach 
a threshold of effect.
We now extend these findings by taking a more nuanced 
and detailed approach to the data. Previous research has 
identified the need for personalised fall prevention strate-
gies [1], but until the drivers of falls (both primary and sec-
ondary features) are more fully understood this is difficult 
to achieve. Characteristics that identify falls risk may differ 
for established and new fallers, and also influence fall fre-
quency and the circumstances in which falls occur [8, 9]. In 
this study, we document evolution of falls over 54 months 
from diagnosis in an incident cohort of PD. We examine 
baseline characteristics of emergent fallers and non-fallers 
over 54 months to identify features that precipitate and alter-
natively protect from falls. We identify baseline features 
that discriminate fallers from falls-naïve at 54 months from 
diagnosis; identify protective features in people who remain 
falls-naïve; explore baseline differences in falls risk in single 
versus recurrent falls; and explore the impact of a previous 
fall on fall risk characteristics.
Methods
Participants
The methodology has been described in full in the earlier 
publication and elsewhere [3, 10–12], and brief details only 
are given here. Participants were recruited into ICICLE-
GAIT within 4 months of diagnosis. This is a collaborative 
study with ICICLE-PD, an incident cohort study (Incidence 
of Cognitive Impairment in Cohorts with Longitudinal Eval-
uation—Parkinson’s disease) conducted between June 2009 
and December 2011. Participants were optimally medicated 
and tested ‘on’ medication for clinical, gait and cognitive 
measures, which were defined as 1 h after medication. All 
testing took place at the Clinical Ageing Research Unit, 
Newcastle University. The study was approved by the New-
castle and North Tyneside Research Ethics Committee and 
all participants gave informed consent.
Clinical assessment
Disease severity was measured using the movement disor-
der society (MDS)-revised unified Parkinson’s disease rat-
ing scale (UPDRS) and Hoehn and Yahr (H&Y) stage [13]. 
PIGD scores and motor phenotype were determined accord-
ing to the MDS-UPDRS revision [14]. Balance self-efficacy 
was measured using the activities balance self confidence 
scale [15], fatigue with the multidimensional fatigue inven-
tory [16] and depression with the geriatric depression scale 
(GDS) [17]. The presence or absence of freezing of gait 
(FoG) was calculated from the new FOG score [18] Levo-
dopa equivalent daily dose (LEDD) scores were calculated 
for each patient [19]. Systolic and diastolic blood pressures 
were recorded in the supine position after 10 min rest and 
then 3 min after standing. Orthostatic hypotension was 
defined as a 20 mmHg fall in systolic BP and/or a 10 mmHg 
in diastolic BP [20].
Gait assessment and outcomes
Gait was assessed using a 7 m long × 0.6 m wide instru-
mented walkway (Platinum model Gaitrite, software version 
4.5, CIR systems, United States of America). Participants 
were instructed to walk at their comfortable walking pace for 
2 min around a 25 m oval circuit under single and dual task 
conditions. We measured 16 independent gait characteristics 
that conform to a model of gait that has been validated in PD 
and comprises five independent domains (pace, variability, 
rhythm, asymmetry and postural control) [21].
Cognitive assessment and outcomes
Cognitive tests have been described in full elsewhere, as 
noted above. Briefly, global cognition was measured with 
the Montreal Cognitive Assessment (MoCA) [22]. Attention 
was assessed with the cognitive drug research (CDR) battery 
[23] and tests from the CANTAB battery measured visual 
memory and executive function [24]. Visuospatial function 
was assessed with the first item of the MoCA which included 
clock drawing, cube copying and a short version of the Trail 
Making Test B. Two items from the Parkinson’s disease non-
motor-symptoms questionnaire [25] were used to record sub-
jective cognitive complaint: participants were asked whether 
in the last month they had experienced problems remember-
ing things that have happened recently or forgetting to do 
things (item 12) and difficulty in concentrating or staying 
focused (item 15).
Falls diaries
A fall was defined as ‘unintentionally coming to rest on 
the ground or other lower surface without being exposed 
to overwhelming external force or a major internal event’ 
[26] and falls were recorded prospectively using PROFANE 
recommendations. Falls diaries were sent out on a monthly 
basis with a pre-paid return envelope in which participants 
were asked to record if they had fallen in the past month. 
If so, they were prompted to provide the date and time of 
each fall as well as location, preceding activity, perceived 
cause, position in which they landed on the floor and mode 
J Neurol 
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of recovery. All falls reported in the diaries were followed up 
with a telephone call from a senior research physiotherapist 
(DM, HH) to verify information and rectify any missing 
data. Reasons for non-returned diaries were ascertained by 
follow-up telephone calls, and participants were encouraged 
to continue if appropriate. If diaries for single fallers were 
incomplete, their data could not be used to establish fre-
quency because their status was unclear. Those who identi-
fied as retrospective fallers were reported as a ‘single faller’ 
at baseline. We classified falls using the falls-related activi-
ties classification [8, 9] to discern the type of fall experi-
enced by single fallers.
Data analysis
Falls occur along a continuous timeline, but for the purposes 
of this study we annotated falls at discrete and evenly spaced 
intervals that corresponded with follow-up assessments. 
Data from monthly diaries were inspected and a five-point 
ordinal scale was used to reflect falls status: 0 = falls-naïve 
at 54 months; 1 = retrospective faller (self-reported faller at 
study entry); 2 = new faller between baseline and 18 months; 
3 = new faller between 18 and 36 months; 4 = new faller 
between 36 and 54 months. We first described baseline char-
acteristics for each group and examined between group dif-
ferences. We then selected outcomes to represent the broad 
scope of characteristics described in Table 1 and conducted 
two analyses. The first compared fallers versus non-fallers 
at 54 months with inclusion and then exclusion of baseline 
fallers; and the second compared single versus recurrent fall-
ers. For the latter analysis, fall frequency was determined 
by inspection of falls diaries and only participants with 
completed diaries over 54 months were included. Finally, 
we analysed proportion of fallers at discrete intervals over 
54 months for four outcomes which were shown to be sig-
nificantly different between groups: Hoehn and Yahr stag-
ing, subjective cognitive complaint, and gait speed and gait 
variability. These four outcomes were dichotomised around 
median scores for the total cohort (n = 99). Because of non-
normal distribution of data and small sample size, we used 
non-parametric tests to describe and examine between group 
differences for all analyses. Given the exploratory nature of 
the analysis we accepted an alpha level of P < 0.05.
Results
One hundred and twenty-one people with incident PD 
were recruited into ICICLE-GAIT. Two participants 
were re-diagnosed and two did not participate in the falls 
study, leaving a total of 117 participants. Eighteen par-
ticipants whose falls status was unknown withdrew from 
the falls study over the 54 months, with data available for 
99 participants. Of these, 26 (26.2%) reported at least one 
fall in the past year (retrospective faller). From baseline to 
18 months 30 (30.3%) prospective fallers were recorded, 
from 18 to 36 months 17 new fallers (17.1%), and from 
36 to 54 months 6 (6.0%) new fallers. By 54 months 79 
(79.7%) of the total cohort had fallen and 20 (20.3%) 
were still falls-naive. Prospective data for fall frequency 
were available for 65 participants with complete diaries to 
54 months. Seven participants (10.7%) were single fallers, 
and 58 (89.3%) recurrent. Participants who fell did not 
revert to non-fallers.
Table 1 describes characteristics of fallers and non-fall-
ers and between group differences. Descriptive data shows 
that outcomes were almost universally better for the 20 
non-fallers compared with fallers at any time point. Over 
54 months, disease severity, gait, and outcomes that broadly 
represent self-efficacy (including subjective cognitive com-
plaint) were the strongest discriminative features for new 
fallers at each time point. However, the spread of H&Y 
scores suggests some inconsistencies. For example, fallers 
at 36 months who presented as H&Y III comprised only 
1 of a total of 17 (5.6%). A similar discrepancy occurred 
in retrospective fallers, with only 6 of the 26 (23%) clas-
sified as H&Y II. Although the proportion of new fallers 
increased rapidly from baseline to 18 months especially for 
those with H&YIII, around a third of H&Y I had also fallen 
by this stage. Median PIGD score was 0.60 for fallers at 
baseline through to 36 months, lowering to 0.40 for fall-
ers at 54 months and for non-fallers. Features of gait from 
pace and variability domains discriminated across groups, 
with non-fallers presenting with the fastest gait. Freezing 
of gait was most evident in retrospective fallers. Subjective 
cognitive complaint was the only cognitive variable to sig-
nificantly discriminate across groups with 92% of baseline 
fallers reporting subjective complaint, gradually lowering 
to 40% for 54 month fallers. The influence of retrospective 
fallers on falls status at 54 months is illustrated in Table 2, 
which shows stronger between group (fallers versus non-
fallers) discrimination for a broader range of outcomes when 
retrospective fallers are included in analysis. Differences in 
single leg time, step velocity and PIGD are the only vari-
ables retained as significant when retrospective fallers are 
excluded from analysis. Table 3 shows selected baseline 
characteristics for seven participants who comprised the 
single faller cohort, who were compared with recurrent fall-
ers (n = 58) at 54 months. Single fallers were significantly 
younger by 15 years, and presented with higher MoCA 
visuospatial scores which trended towards significance 
(P = 0.05). When single falls were classified according to 
pre-fall event [9] three falls occurred during advanced activ-
ity (one whilst hiking and two whilst walking outdoors); 
three during combined movement (stair descent); and one 
during postural transition (rising from sitting to stand).
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Table 1  Baseline demographic and clinical characteristics of retrospective fallers and new fallers at 18 month intervals over 54 months
Retrospective (base-
line) fallers
Prospective fallers Non-fallers P
(n = 26) 18 m (n = 30) 36 m (n = 17) 54 m (n = 6) (n = 20)
Age (years) 66.9 (13.2) 71.9 (13.0) 70.2 (15.9) 70.9 (11.8) 67.6 (16.9) 0.863
BMI 25.5 (6.4) 26.3 (6.1) 25.5 (7.2) 26.1 (5.4) 26.8 (5.6) 0.935
Male, n (%) 13 (50) 23 (76.6) 9 (52.9) 5 (83.3) 16 (80) 0.078
Levodopa prescribed, 
n (%)
13 (50) 7 (23.3) 5 (29.4) 1 (16.6) 6 (30) 0.216
LEDD (mg day−1) 180.0 (285.0) 100.0 (57.5) 137.5 (200.0) 100.0 (255.5) 135.0 (165.0) 0.174
Dopamine agonist, 
n (%)
9 (34.6) 9 (30) 7 (41.1) 1 (16.6) 8 (40) 0.660
Disease severity
 H&Y score, n (%) 
I, II, III
2 (7.6), 18 (69.2), 6 
(23.0)
6 (20), 12(60), 12 
(60)
6 (35.2), 10(58.8), 
1 (5.8)
0 (0), 6 (100), 0 (0) 8 (40), 11(55),  1(5) 0.002
 Motor phenotype, 
n (%) (PIGD, ID, 
TD)
14 (53.8), 3 (11.5), 9 
(34.6)
17 (56.6),4 (13.3), 
9(30)
9 (52.9), 1 (5.8), 7 
(41.1)
1(16.6), 1 (16.6), 4 
(66.6)
6 (30), 1 (5), 13 (65) 0.015
 PIGD score (0–4) 0.60 (0.8) 0.60 (0.4) 0.60 (0.5) 0.40 (0.4) 0.40 (0.4) 0.022
 Tremor score (0–4) 0.75 (0.50) 0.55 (0.55) 0.64 (0.60) 0.77 (0.53) 0.72 (0.53) 0.233
 UPDRS II (0–52) 12.0 (8) 11.0 (5) 11.0 (10) 9.0 (10) 7.0 (8) 0.144
 UPDRS III (0–132) 29.0 (15.7) 27.0 (12.5) 26.0 (15.5) 23.0 (17.0) 19.5 (11.7) 0.058
 FOG, n (%) 5 (19.2) 1 (3.3) 1 (5.8) 0 (0) 2 (10.0) 0.370
 NFOG score (0–28; 
higher worse)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0.726
 Orthostatic hypo-
tension, n (%)
6 (23.0) 5 (16.6) 1 (5.8) 3 (50.0) 2 (10.0) 0.493
 GDS (0–15; higher 
worse)
3.0 (3) 3.0 (3) 2.0 (2) 2.0 (3) 2.0 (1.0) 0.140
 ABC score (0–100; 
higher better)
69.0 (44.6) 89.3 (26.3) 93.5 (20.9) 93.6 (17.1) 96.2 (18.9) <0.001
 Total fatigue 
(20–100; higher 
worse)
64.0 (17) 49.0 (19) 46.0 (21) 51.0 (19) 37.5 (34) 0.000
Cognitive outcomes
 Years of education 12.0 (6) 11.5 (4) 11.0 (8) 13.0 (4) 11.5 (6)
 MoCA (0–30) 24.5 (7.2) 25.0 (5.2) 26.0 (4.7) 27.5 (3.5) 27.0 (5.5) 0.232
 MoCA visuospatial 
(Item 1) (0–5)
4.0 (2.0) 4.0 (2.0) 5.0 (1.7) 5.0 (0.25) 5.0 (1.0) 0.205
 Subjective cogni-
tive complaint, 
n (%)
24 (92.3) 19 (63.3) 10 (58.8) 3 (50.0) 8 (40) <0.001
 PoA (mean SRT, 
CRT, digit vigi-
lance)
1362 (260) 1357 (156) 1246(336) 1360(300) 1287(154) 0.227
 PRM (mean correct 
latency)
2165 (1510) 2072 (646) 2180 (902) 2023 (660) 1987 (753) 0.604
 SRM (mean correct 
latency)
2024 (1434) 2128 (892) 2335 (525) 2089 (924) 1971 (758) 0.965
 OTS (mean correct 
latency)
22,145 (18,658) 22,452 (15,615) 20,500 (11,122) 12,802 (6144) 19,039 (13,998) 0.338
 OTS (mean choices 
correct)
1.2 (0.21) 1.2 (0.30) 1.3 (0.37) 1.5 (0.55) 1.4 (0.50) 0.328
Motor outcomes
 Single leg stance 
(s) (higher better)
6.7 (20.5) 9.9 (19.8) 5.3 (15.6) 18.5 (11.2) 13.2 (23.4) 0.092
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Figure 1 shows proportion of non-fallers at each time 
point for four variables. Figure 1a shows an early, steep 
decline in proportion of non-fallers for H&Y III followed 
by a plateau (P = 0.004; Chi-square test); Fig. 1b shows 
a similar line for participants with and without subjective 
cognitive complaint but a greater proportion of fallers 
Significant values are indicated in bold
Data presented as the group median (IQR) unless otherwise stated
All comparisons using Kruskal–Wallis test apart from binary outcomes [Chi-square (χ2) test]
LEDD levodopa equivalent daily dose, PIGD postural instability and gait disorder subscale UPDDRS, UPDRS III united Parkinson’s disease 
rating scale, NFOG new freezing of gait questionnaire, ABCs activities balance confidence-specific scale, GDS geriatric depression scale, MoCA 
Montreal cognitive assessment, MCR motor cognitive risk, PoA power of attention, PRM pattern recognition memory, SRM spatial recognition 
memory, OTS one touch stocking of Cambridge
Table 1  (continued)
Retrospective (base-
line) fallers
Prospective fallers Non-fallers P
(n = 26) 18 m (n = 30) 36 m (n = 17) 54 m (n = 6) (n = 20)
 Timed chair stand 
(s) (higher worse)
13.6 (4.9) 14.6 (5.9) 12.4 (4.7) 14.6 (4.5) 13.3 (5.4) 0.595
Gait outcomes
 Pace domain
  Step velocity 
(m/s)
1.05 (0.27) 1.03 (0.24) 1.11 (0.36) 1.12 (0.24) 1.21 (0.14) 0.021
  Step length (m) 0.590 (0.11) 0.615 (0.14) 0.621 (0.12) 0.658 (0.14) 0.657 (0.10) 0.044
  Swing time vari-
ability (ms)
20.0 (11.6) 16.9 (8.70 15.3 (6.3) 15.4 (2.6) 13.7 (7.2)
 Rhythm domain
  Mean step time 
(ms)
551.0 (63.8) 579.6 (82.1) 533.5 (59.0) 569.5 (91.3) 537.5 (42.4) 0.215
  Mean swing time 
(ms)
381.7 (32.3) 391.4 (51.1) 399.6 (49.1) 395.1 (62.9) 383.0 (40.8) 0.421
  Mean stance time 
(ms)
723.7 (98.5) 749.1 (123.4) 695.7 (100.1) 752.0 (104.5) 699.9 (50.0) 0.074
 Variability domain
  Step velocity 
variability 
(m s−1)
0.057 (0.020 0.051 (0.01) 0.047 (0.01) 0.048 (0.01) 0.048 (0.01) 0.039
  Step length vari-
ability (m)
0.024 (0.01) 0.022 (0.00) 0.018 (0.00) 0.016 (0.00) 0.020 (0.01) 0.044
  Step time vari-
ability (ms)
22.2 (11.5) 19.0 (8.4) 14.5 (8.5) 15.8 (2.2) 15.3 (8.0) 0.016
  Stance time vari-
ability (ms)
26.1 (16.9) 23.3 (8.7) 15.9 (10.3) 16.6 (4.2) 16.5 (7.3) 0.002
 Asymmetry domain
  Swing time asym-
metry (ms)
12.3 (8.3) 11.8 (21.8) 13.4 (26.0) 19.0 (12.0) 7.6 (10.1) 0.082
  Step time asym-
metry (ms)
14.7 (20.1) 13.3 (27.3) 19.8 (20.4) 20.0 (8.0) 10.4 (15.2) 0.460
  Stance time 
asymmetry (ms)
12.6 (9.9) 11.1 (20.4) 11.1 (27.0) 16.7 (9.7) 10.1 (7.80 0.453
 Postural control domain
  Step length asym-
metry (m)
0.022 (0.03) 0.014 (0.02) 0.020 (0.04) 0.030 (0.02) 0.019 (0.02) 0.494
  Mean step width 
(m)
0.105 (0.05) 0.086 (0.05) 0.086 (0.03) 0.085 (0.03) 0.080 (0.04) 0.806
  Step width vari-
ability (m)
0.018 (0.00) .0.018 (0.00) 0.019 (0.00) .0.016 (0.00) 0.017 (0.00) 0.988
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across all time points for participants who reported a 
complaint at baseline (P  =  0.017; Chi-square test); 
Fig. 1c, d show comparable trajectories for gait speed 
and stance time variability, with faster speed and lower 
variability protective of falls, both of which significantly 
discriminated across groups (P = 0.019 and P = 0.013, 
respectively, Kruskal–Wallis test).
Discussion
This study is, to our knowledge, the first to describe the natu-
ral history of falls in people with PD over an extended period 
of time and relate this to prognostic falls risk. Participants 
experienced their first fall soon after diagnosis, with most 
new fallers appearing before 36 months. Over the 54 months 
Table 2  Comparison of baseline characteristics of all fallers and non-fallers at 54 months, including and excluding retrospective (baseline) fall-
ers
Significant values are indicated in bold
Data presented as the group median (IQR) unless otherwise stated
Total sample size for 54 m falls cohort (n = 95) is smaller than the total cohort described in Table 1 (n = 99) because four participants (three ret-
rospective non-fallers and one retrospective faller) were included in baseline data but did not participate in the prospective study
All Mann–Whitney other than H&Y (χ2 test)
a  Non-fallers at 54 months include three retrospective fallers
54-month falls cohort including retrospective 
fallers
P 54-month falls cohort excluding retrospective 
fallers
P
Fallers (n = 72) Non-fallers (n = 23)a Fallers (n = 53) Non-fallers (n = 20)
Age 70.0 (12.8) 66.2 (17.2) 0.380 71.6 (12.0) 67.6 (16.9) 0.451
BMI 26.2 (6.7) 26.2 (5.0) 0.555 26.1 (6.7) 26.8 (5.6) 0.951
UPDRS III 26.5 (12.5) 21.9 (12.0) 0.043 26.0 (13.5) 19.5 (11.7) 0.083
PIGD 0.60 (0.6) 0.40 (0.4) 0.005 0.60 (0.5) 0.40 (0.4) 0.021
H&Y stage I, II, III, n (%) 13 (18.0) 42 
(58.4), 17 (23.6)
9 (39.1) 13 (56.5), 1 (4.4) 0.034 12 (22.6), 28 
(52.8), 13 (24.6)
8(40.0) 11(55.0), 1(5.0) 0.106
Single leg time 7.8 (18.9) 15.3 (23.5) 0.020 8.0 (19.3) 13.2 (23.4) 0.036
ABCs 87.9 (27.3) 95.6 (11.2) 0.029 92.0 (23.9) 96.2 (18.9) 0.202
MoCA total 26.0 (4.0) 27.0 (6.0) 0.140 26.0 (4.7) 27.0 (5.5) 0.379
MoCA visuospatial 5 (2.0) 5 (1.0) 0.388 5.0 (2.0) 5 (1.0) 0.877
PoA 1346 (204) 1282 (187) 0.075 1348 (189) 1287 (154) 0.212
Step velocity 1.08 (0.26) 1.21 (0.15) 0.001 1.09 (0.25) 1.21 (0.14) 0.006
Stance time SD 21.9 (11) 16.4 (5.4) 0.012 21.3(11.0) 16.5 (7.3) 0.071
Table 3  Comparison of 
baseline characteristics of single 
versus recurrent fallers over 
54 months
Significant value is indicated in bold
Data presented as the group median (IQR) unless otherwise stated
* All Mann–Whitney other than H&Y (Chi-square test)
Single fallers (n = 7) Recurrent fallers (n = 58) P*
Age 56.9 (15.7) 71.7 (11.9) 0.013
BMI 25.2 (10.6) 26.3 (5.9) 0.719
UPDRS III 26.0 (8.0) 26.5 (11.7) 0.857
PIGD 0.60 (0.4) 0.60 (0.6) 0.528
H&Y stage I, II, III, n (%) 2 (28.5), 4 (57.2), 1 (14.3) 10 (17.2), 32 (55.2), 16 (27.6) 0.588
Single leg time 22.2 (22.3) 6.9 (18.5) 0.423
ABCs 90.8 (28.1) 85.4 (30.0) 0.315
MoCA total 27.0 (2.5) 25.0 (5.0) 0.082
MoCA visuospatial 5 (5.0) 4.0 (2.0) 0.052
PoA 1244 (302) 1349 (187) 0.186
Step velocity 0.97 (0.5) 1.06 (0.21) 0.642
Stance time SD 18.7 (22.4) 22.2(10.8) 0.612
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only seven participants retained single faller status, suggest-
ing that sporadic falls are uncommon.
The detailed characterisation of participants who fell 
and those who did not inform early management of falls 
risk. Overall our results show that disease severity and 
gait discriminate new fallers, along with aspects of self-
efficacy which are more evident when retrospective fallers 
are included in analysis. Deficits in postural control (the 
hallmark feature of H&Y III) are evident even in very 
early PD [27] and these results along with differences in 
single leg stance confirm the critical role of postural con-
trol to falls. Whilst these results appear obvious, a more 
nuanced consideration shows the distribution of H&Y 
scores varies across the 54 months, suggesting that char-
acteristics other than disease severity contribute to falls. 
This point to the complexity of falls risk, which is the 
interaction of multiple factors. Our findings are broadly 
consistent with a large body of prognostic falls research, 
some of which has also been carried out in falls-naïve 
cohorts using robust methodology to ascertain falls sta-
tus [28, 29]. An important distinction is that participants 
from these earlier studies had moderately advanced dis-
ease (average duration for both studies 6 years), by which 
time secondary features such as deconditioning are likely 
to influence results. For example, Almeida [28] identified 
self-reported disability status as the strongest significant 
predictor of all falls, suggesting a role for self-efficacy 
which may not appear earlier.
We expected cognition (global cognition, attention and 
executive dysfunction) to emerge as discriminative meas-
ures given their powerful role in modifying falls and the 
presence of early cognitive impairment in PD. Attention 
is a powerful modifier of gait [12] and we anticipated a 
stronger link in this cohort. Cognitive impairment is a sig-
nificant risk factor for falls in older adults and in PD with 
recent evidence suggesting its effect may be underesti-
mated [30]. A recent study exploited the role of cognition 
to falls in PD using a dual task paradigm delivered via 
a virtual reality platform which yielded superior results 
compared with treadmill training alone [7]. The results 
may partly reflect the advanced status of the cohort where 
the association between cognition and falls is likely to be 
Fig. 1  Proportion of non-fallers over 54 months excluding retrospective fallers: a H&Y groups, b subjective cognitive complaint, c gait speed, 
and d stance time variability
 J Neurol
1 3
stronger. Our results did not confirm a significant role for 
cognition, although we may have been underpowered to 
detect differences. Descriptively, scores for global cogni-
tion (MoCA) and power of attention were worse for early 
fallers, as was visuospatial function. Subjective cognitive 
complaint discriminated across groups, however, the sta-
bility of the measure has to our knowledge not been veri-
fied, and cross-sectional data from the larger ICICLE-PD 
study indicates that follow-up scores for subjective cogni-
tive complaint show an inconsistent pattern with many 
participants reverting from a positive score at baseline to 
a negative score at 18 months [31]. A more discreet under-
standing of cognition in falls trajectory and its contribution 
relative to motor dysfunction is required help inform strat-
egies for early intervention. Of interest is a recent study 
reporting comparable fall frequency for people with PD of 
6 years average duration with and without mild cognitive 
impairment [30], suggesting that cognition may emerge 
as an important feature later than this. We anticipated that 
cognitive reserve (resilience against age-induced cogni-
tive change), measured by years of education, would exert 
a protective effect but this was not the case with highly 
comparable outcomes across the falls spectrum.
More broadly, we confirmed that retrospective fallers 
were more globally impaired at baseline than falls-naïve 
participants. Inclusion of retrospective fallers biases findings 
towards more generic features, some of which may reflect 
secondary change occurring in response to falls or age-
related features. For example, scores for balance self-efficacy 
(ABCs) and fatigue were worse for retrospective fallers com-
pared with fallers at all time points. Between group differ-
ences were overall not as strong when retrospective fallers 
were excluded. These findings have important implications 
for understanding falls risk and prioritising treatment. Pre-
dictors of falls will be different when established fallers are 
included in analysis, which is the most common methodol-
ogy. Their inclusion potentially mask important findings.
Single fallers were significantly younger and presented 
with better visuospatial function when compared with recur-
rent fallers. Classification of each single fall event [9] further 
informed about the nature of fall risk for this group and the 
likelihood of recurrence. We published 12-month falls clas-
sification data for this cohort [9] and argue for the need to 
document falls in this broader context so that more useful 
inferences about prognosis can be made.
Limitations to this study include the sample size. There 
were only six new fallers at 54 months, which compromised 
variance in scores. We were underpowered to detect all dis-
criminatory features, indicated by some P values which 
denote a trend towards significance. Counter to this argu-
ment is that the study design involved a comprehensive test 
battery which in turn provides in-depth descriptive data. 
Future analysis will review falls trajectory over a longer time 
period and identify prognostic features.
In conclusion, new fallers emerge consistently over 
54 months in newly diagnosed PD, although most occur 
early after diagnosis and become recurrent. New fallers 
can be categorized by baseline performance, especially for 
measures of disease severity and motor function. The con-
tribution of cognition to falls status is less emphatic in this 
early group. Retrospective fallers present with more global 
features of decline, some of which may be age-related. These 
findings help guide clinical decision-making and emphasize 
the need for early interventions that target in particular gait 
and postural control deficit.
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